SCHEMBL19861815

SCHEMBL19861815

CCC(C)n1cnc(C(N)=O)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.38
ADORA1 P30542 4/20 0.37
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
EIF4E P06730 1/20 0.37
CYP3A4 P08684 1/20 0.37
TOP1 P11387 1/20 0.37
TSHR P16473 1/20 0.37
THPO P40225 1/20 0.37
PMP22 Q01453 1/20 0.37
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
SLC6A3 Q01959 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
TGFBR1 P36897 1/20 0.33
TGFBR2 P37173 1/20 0.33
ADORA2A P29274 2/20 0.33
ADORA2B P29275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22399607 0.87 ACHE (0.40) ACHEADORA1LMNASMN1; SMN2ALDH1A1
SCHEMBL784347 0.82 ADORA1 (0.40) ACHEADORA1LMNASMN1; SMN2ALDH1A1
SCHEMBL23633811 0.81 LMNA (0.34) ADORA1LMNASMN1; SMN2ALDH1A1GLA
SCHEMBL11851306 0.80 LMNA (0.35) ADORA1LMNASMN1; SMN2ALDH1A1GLA
SCHEMBL18977796 0.78 LMNA (0.35) ADORA1LMNASMN1; SMN2ALDH1A1GLA
SCHEMBL25161951 0.74 MAPT (0.38) LMNAALDH1A1CYP3A4HTR2BSLC6A3
SCHEMBL30587540 0.73 TDP1 (0.42) LMNAALDH1A1CYP3A4MAPK1L3MBTL1
SCHEMBL30587581 0.73 TDP1 (0.42) LMNAALDH1A1CYP3A4MAPK1L3MBTL1
SCHEMBL18750762 0.72 LMNA (0.37) ADORA1LMNASMN1; SMN2ALDH1A1GLA
SCHEMBL13757852 0.72 LMNA (0.40) ADORA1LMNASMN1; SMN2ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11376272-B2 Methods of modulating immune activity FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2022-07-05 US disclosed
US-20210299155-A1 METHODS OF MODULATING IMMUNE ACTIVITY FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-30 US disclosed
US-9890188-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2018-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11376272-B2 Methods of modulating immune activity STING1, IRF3, CGAS ACHE 3936/4885ADORA1 34/4885LMNA 3096/4885
US-20210299155-A1 METHODS OF MODULATING IMMUNE ACTIVITY STING1, IRF3, CGAS ACHE 3724/4885ADORA1 30/4885LMNA 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.